News

Reduce GlaxoSmithKline Pharmaceuticals: target of Rs 2,600: ICICI Securities
ICICI Securities recommended reduce rating on GlaxoSmithKline Pharmaceuticals with a target price of Rs 2,600 in its research ...
TipRanks on MSN2d
GSK Advances Share Buyback Program with Recent Acquisition
GlaxoSmithKline (GSK) has announced the repurchase of 783,700 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction is part ...
Zacks Investment Research on MSN3d
Glaxo (GSK) Upgraded to Buy: Here's What You Should Know
Investors might want to bet on GSK (GSK), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the ...
GSK Pharma Q4 profit rises 35% to ₹263 crore on strong brand growth
GSK Pharma reports 35 per cent YoY rise in Q4FY25 profit led by gains in general medicines and vaccines; oncology launches ...
Applied Clinical Trials Online1d
iTeos and GSK Halt TIGIT Antibody Belrestotug Development After Phase II Trials Miss Efficacy Marks in NSCLC and HNSCC
Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...
Reuters2d
India's GlaxoSmithKline Pharma reports profit rise on strong demand
May 13 (Reuters) - India's GlaxoSmithKline Pharmaceuticals ... The Indian unit of British drugmaker GSK (GSK.L), opens new tab reported consolidated profit of 2.63 billion rupees ($30.86 million ...